Nephrology Evaluation - March 17, 2018

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1	The information and/or skills learned will enhance my professional competence or ability. - 0
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 0

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Explain key discoveries driving current clinical trials.	Explain key discoveries driving current clinical trials. - 5	Explain key discoveries driving current clinical trials. - 4	Explain key discoveries driving current clinical trials. - 3	Explain key discoveries driving current clinical trials. - 2	Explain key discoveries driving current clinical trials. - 1	Explain key discoveries driving current clinical trials. - 0
Describe the importance and the strategies when identifying clinically relevant targets.	Describe the importance and the strategies when identifying clinically relevant targets. - 5	Describe the importance and the strategies when identifying clinically relevant targets. - 4	Describe the importance and the strategies when identifying clinically relevant targets. - 3	Describe the importance and the strategies when identifying clinically relevant targets. - 2	Describe the importance and the strategies when identifying clinically relevant targets. - 1	Describe the importance and the strategies when identifying clinically relevant targets. - 0
Discuss recent advances in diagnosis of genetic disorders.	Discuss recent advances in diagnosis of genetic disorders. - 5	Discuss recent advances in diagnosis of genetic disorders. - 4	Discuss recent advances in diagnosis of genetic disorders. - 3	Discuss recent advances in diagnosis of genetic disorders. - 2	Discuss recent advances in diagnosis of genetic disorders. - 1	Discuss recent advances in diagnosis of genetic disorders. - 0
Identify case-based examples of how a genetic diagnosis can be used in the clinic. Summarize the guidelines for screening and management of diabetic kidney disease (DKD).	Identify case-based examples of how a genetic diagnosis can be used in the clinic. Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 5	Identify case-based examples of how a genetic diagnosis can be used in the clinic. Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 4	Identify case-based examples of how a genetic diagnosis can be used in the clinic. Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 3	Identify case-based examples of how a genetic diagnosis can be used in the clinic. Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 2	Identify case-based examples of how a genetic diagnosis can be used in the clinic. Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 1	Identify case-based examples of how a genetic diagnosis can be used in the clinic. Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 0
Summarize the guidelines for screening and management of diabetic kidney disease (DKD).	Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 5	Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 4	Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 3	Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 2	Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 1	Summarize the guidelines for screening and management of diabetic kidney disease (DKD). - 0
Explain the contribution of blood pressure control with different agents on DKD development and progression.	Explain the contribution of blood pressure control with different agents on DKD development and progression. - 5	Explain the contribution of blood pressure control with different agents on DKD development and progression. - 4	Explain the contribution of blood pressure control with different agents on DKD development and progression. - 3	Explain the contribution of blood pressure control with different agents on DKD development and progression. - 2	Explain the contribution of blood pressure control with different agents on DKD development and progression. - 1	Explain the contribution of blood pressure control with different agents on DKD development and progression. - 0
Describe how new biomarkers can help to stratify patients.	Describe how new biomarkers can help to stratify patients. - 5	Describe how new biomarkers can help to stratify patients. - 4	Describe how new biomarkers can help to stratify patients. - 3	Describe how new biomarkers can help to stratify patients. - 2	Describe how new biomarkers can help to stratify patients. - 1	Describe how new biomarkers can help to stratify patients. - 0
Summarize the contribution of different hypoglycemia agents on DKD development and progression.	Summarize the contribution of different hypoglycemia agents on DKD development and progression. - 5	Summarize the contribution of different hypoglycemia agents on DKD development and progression. - 4	Summarize the contribution of different hypoglycemia agents on DKD development and progression. - 3	Summarize the contribution of different hypoglycemia agents on DKD development and progression. - 2	Summarize the contribution of different hypoglycemia agents on DKD development and progression. - 1	Summarize the contribution of different hypoglycemia agents on DKD development and progression. - 0
Identify and diagnose AKI syndromes in critically ill patients.	Identify and diagnose AKI syndromes in critically ill patients. - 5	Identify and diagnose AKI syndromes in critically ill patients. - 4	Identify and diagnose AKI syndromes in critically ill patients. - 3	Identify and diagnose AKI syndromes in critically ill patients. - 2	Identify and diagnose AKI syndromes in critically ill patients. - 1	Identify and diagnose AKI syndromes in critically ill patients. - 0
Implement treatment plans for the AKI patient.	Implement treatment plans for the AKI patient. - 5	Implement treatment plans for the AKI patient. - 4	Implement treatment plans for the AKI patient. - 3	Implement treatment plans for the AKI patient. - 2	Implement treatment plans for the AKI patient. - 1	Implement treatment plans for the AKI patient. - 0
Examine novel treatments being investigated.	Examine novel treatments being investigated. - 5	Examine novel treatments being investigated. - 4	Examine novel treatments being investigated. - 3	Examine novel treatments being investigated. - 2	Examine novel treatments being investigated. - 1	Examine novel treatments being investigated. - 0

How effective were the following speakers in meeting their learning objectives? *

Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective Speakers are listed according to the lecture schedule.

	5	4	3	2	1
Podocyte targets for the practicing nephrologists - Alessia Fornoni, M.D., Ph.D.	Podocyte targets for the practicing nephrologists - Alessia Fornoni, M.D., Ph.D. - 5	Podocyte targets for the practicing nephrologists - Alessia Fornoni, M.D., Ph.D. - 4	Podocyte targets for the practicing nephrologists - Alessia Fornoni, M.D., Ph.D. - 3	Podocyte targets for the practicing nephrologists - Alessia Fornoni, M.D., Ph.D. - 2	Podocyte targets for the practicing nephrologists - Alessia Fornoni, M.D., Ph.D. - 1
Genetics in Clinical Nephrology - Jai Radhakrishnan, M.D., M.S.	Genetics in Clinical Nephrology - Jai Radhakrishnan, M.D., M.S. - 5	Genetics in Clinical Nephrology - Jai Radhakrishnan, M.D., M.S. - 4	Genetics in Clinical Nephrology - Jai Radhakrishnan, M.D., M.S. - 3	Genetics in Clinical Nephrology - Jai Radhakrishnan, M.D., M.S. - 2	Genetics in Clinical Nephrology - Jai Radhakrishnan, M.D., M.S. - 1
Diabetes and Kidney Disease - Alessia Fornoni, M.D., M.S.	Diabetes and Kidney Disease - Alessia Fornoni, M.D., M.S. - 5	Diabetes and Kidney Disease - Alessia Fornoni, M.D., M.S. - 4	Diabetes and Kidney Disease - Alessia Fornoni, M.D., M.S. - 3	Diabetes and Kidney Disease - Alessia Fornoni, M.D., M.S. - 2	Diabetes and Kidney Disease - Alessia Fornoni, M.D., M.S. - 1
Acute Kidney Injury (AKI) in Critically Ill Patients - Jai Radhakrishnan, M.D., M.S.	Acute Kidney Injury (AKI) in Critically Ill Patients - Jai Radhakrishnan, M.D., M.S. - 5	Acute Kidney Injury (AKI) in Critically Ill Patients - Jai Radhakrishnan, M.D., M.S. - 4	Acute Kidney Injury (AKI) in Critically Ill Patients - Jai Radhakrishnan, M.D., M.S. - 3	Acute Kidney Injury (AKI) in Critically Ill Patients - Jai Radhakrishnan, M.D., M.S. - 2	Acute Kidney Injury (AKI) in Critically Ill Patients - Jai Radhakrishnan, M.D., M.S. - 1

Was this course fair, balanced and without commercial bias? *

Yes

No

If you checked "No,” please explain why: *

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

Is this your first time attending this symposium? *

Yes

No

How did you hear about us? *

Would you attend this symposium again next year? *

Yes

No

If you checked "No,” please tell us why: *

Would you recommend this symposium to a colleague? *

If you checked "No,” please explain why you would not recommend this course: *

Please list specific changes you intend to implement in your daily practice as a result of attending this activity. *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so.

Suggested topics and/or speakers you would like for future symposiums.

Comments

Name

You are here

Nephrology Evaluation - March 17, 2018